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Gout is a common inflammatory disease in 
which pathogenesis is almost entirely supported by 
the deposition of elevated levels of urate crystals 
in many different tissues, particularly the joints 
and the kidneys [1]. Gout is also associated with an 
increase in risk of cardiovascular disease (in par-
ticular coronary artery disease) which significantly 
contributes to higher mortality and morbidity [2]. 
The clinical manifestations of gout are usually her-
alded by an asymptomatic increase in plasma levels 
of uric acid, this must be considered as a typical 
biomarker of the disease. An individuals’ risk of 
gout is proportional to absolute circulating levels 
of uric acid and increases progressively with the 
number of attacks and poor control of uric acid lev-
els [3]. Froma biochemical point of view, uric acid 
is the final step of a biochemical cascade aimed at 
the degradation of purines [4] and is largely based 
on the activation of the enzyme xantine-oxido-
-reductase (XOR) that catalyzes the last two steps 
of the reaction, i.e. those leading to the production 
of uric acid. This can explain why the treatment of 
gout and the prevention of its clinical complications 
are largely based on the administration of drugs 
that reduce the levels of serum uric acid through 
the inhibition of the XOR (“XO-inhibitors”).
In current clinical practice, allopurinol and 
febuxostat are the two drugs commonly used to 
inhibit XOR, leading to a significant reduction of 
serum levels of uric acid and a decrease in the 
recurrence of gout attacks and flares [5]. They are 
recommended as the first-line drugs by all major 
guidelines regarding the management of inflamma-
tory diseases, it is also mentioned that these two 
drugs have been shown to exert a preventive effect 
on cardiovascular disease and may thus be consid-
ered in the management of patients with gout in 
whom cardiovascular prevention is a fundamental 
therapeutic goal, such as when  cardiovascular risk 
is high or very high.
In a recent issue of the Cardiology Journal [6], 
a position paper was published dealing with the 
use of XO-inhibitors in patients with gout and sum-
marized most of the available information about 
their efficacy and safety. This paper reviewed data 
showing that febuxostat provides a potent and 
highly selective inhibition of XO, and thus greater 
hypouricemic activity vs the commonly used doses 
of allopurinol [7]. It was also mentioned, however, 
that results of the CARES study [8] reported an 
increased risk of cardiovascular death in patients 
treated with febuxostat and subsequently led 
some regulatory authorities to issue a cautionary 
statement on the widespread use of the drug. It 
is herein emphasized that the limitations of the 
CARES study (which extend to trial design) as 
well as evidence presented after its publication 
largely remove the arguments against the use of 
febuxostat in patients with gout. As mentioned 
in the paper [6] the CARES study did not include 
a non-actively treated or placebo control group, 
which importantly limits the interpretation of its 
findings. Furthermore, the study had been carried 
out in patients with moderate-to-severe obesity 
and had a history of a major cardiovascular event, 
namely a very high cardiovascular risk population 
that was far from the average population of patients 
suffering from gout in clinical practice. Finally, 
and most importantly, a recently published meta-
analysis of 35 studies did not show a significant 
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difference between febuxostat and allopurinol for 
the risk of cardiovascular events (p = 0.37) [9]. 
Thus, there appears to be no reason for concern 
about the use of febuxostat in the general popula-
tion affected by gout, strictly limiting the debated 
question about a highly selected group of patients 
in whom gout, complicated by obesity and very high 
cardiovascular risk. Even in these patients, how-
ever, a favorable cardiovascular effect of febuxostat 
cannot be excluded because in the CARES study, 
the lack of a placebo arm did not allow a provision 
for information on the overall cardiovascular effects 
of reduction vs. no reduction of uric acid. 
These re-assuring conclusions have been 
strongly supported by the studies presented dur-
ing an international meeting on uric acid and 
XO-inhibitors held in Italy under the auspices of 
the European Society of Hypertension in Novem-
ber 2018. In the FREED study (Kojima S, ESC 
Congress 2018) [10], over 1000 elderly patients 
with elevated serum uric acid levels (between 
7.0 and 9.0 mg/day) and one or more risk factors 
for cerebral, cardiovascular, or renal disease were 
treated with febuxostat (up to 40 mg daily) or 
been given no or other hypouricemic drugs (100 
mg daily of allopurinol). After 3 years, a 25% re-
duction in the risk of a composite of death for any 
cause, cerebrovascular disease, non-fatal coronary 
disease, heart failure requiring hospitalization, 
atherosclerotic disease requiring treatment, renal 
impairment, and atrial fibrillation was observed in 
febuxostat compared to the non-febuxostat group. 
Febuxostat also prevented the development and 
progression of chronic kidney disease. In the mul-
ticenter FEATHER study, patients with different 
degrees of chronic kidney disease (n = 467) were 
randomly assigned to receive febuxostat or placebo 
for 108 weeks. Treatment with febuxostat did not 
significantly prevent the decline in kidney function 
in patients with stage 3 chronic kidney disease 
and asymptomatic high uric acid [11]. However, in 
a pre-specified subgroup analysis on patients with 
different degrees of renal dysfunction (presence/ 
/absence of proteinuria and different levels of serum 
creatinine) febuxostat exhibited a favorable effect 
when renal function was better preserved. In addi-
tion, a detailed analysis of the incidence of severe 
adverse effects showed that the drug was associ-
ated with a lower incidence of major cardiovascular 
and renal complications (Table 1), clearly support-
ing the adequate safety profile of the drug. Finally, 
a recent comparative analysis was carried out on 
a database of United States Medicare (2008–2013), 
using propensity score matching (ratio 1:3) to limit 
confounding [12]. The analysis included 99,744 
elderly (age > 65 years) patients with gout who 
initiated urate lowering treatment with febuxostat 
or allopurinol. The incidence of the primary out-
come (hospitalization of myocardial infarction or 
stroke) per 100 person-years was 3.43 and 3.36, 
respectively in patients initiating treatment with 
febuxostat and allopurinol (hazard ratio: 1.01; 95% 
confidence interval: 0.94–1.08). Subgroup and 
sensitivity analyses consistently showed a similar 
cardiovascular risk in both groups, with no overall 
difference in risk of myocardial infarction, stroke, 
new-onset heart failure, coronary revasculariza-
tion, or all-cause mortality as well. These results 
on populations are more clearly representative 
of patients with gout, candidates to which hy-
pouricemic treatment in clinical practice clearly 
support the conclusions about the general safety 
of febuxostat, the only residual query remaining 
were small subgroups of “CARES” patients where 
the impact of hypouricemic treatment must be ad-
dressed by studies with a better controlled design. 
This is in line with a statement recently published 
in Circulation by W.B. White, the leading author 
of the CARES paper: “The unexpected finding of 
an increase in cardiovascular mortality with no 
Table 1. Number of adverse events in chronic kidney disease patients treated with febuxostat or placebo. 
FEATHER Study (from [11] modified).
Events Febuxostat (n = 222) Placebo (n = 219) P 
Renal dysfunction 9 19 0.08
Cardiovascular disorders 4 9 0.2
Stroke 1 2 0.6
Other cardiovascular 3 10 0.08
Blood pressure changes 5 8 0.5
Arrhythmias 4 4 0.9
Total 26 (11.7%) 62 (28.3%) –
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differences in any non-fatal cardiovascular event 
in CARES requires more research in the assess-
ment of cardiovascular safety of xanthine oxidase 
inhibitors” [13]. 
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